Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
N Engl J Med
.
2023 Jun 15;388(24):2299.
doi: 10.1056/NEJMc2304782.
Authors
Brandon Smith
1
,
Priya Engel
2
,
Jashin J Wu
3
Affiliations
1
Drexel University College of Medicine, Philadelphia, PA.
2
California University of Science and Medicine, Colton, CA.
3
University of Miami Miller School of Medicine, Miami, FL jashinwu@gmail.com.
PMID:
37314718
DOI:
10.1056/NEJMc2304782
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal / adverse effects
Dermatitis, Atopic* / drug therapy
Humans
Substances
lebrikizumab
Antibodies, Monoclonal